<DOC>
	<DOCNO>NCT00585507</DOCNO>
	<brief_summary>Fulvestrant proven effective treatment hormone receptor positive metastatic breast cancer . The dose use study far well tolerate may low optimal effectiveness . In study , high dose use see whether improve outcome result .</brief_summary>
	<brief_title>Efficacy Safety 500mg Fulvestrant</brief_title>
	<detailed_description>- Fulvestrant administer intramuscular injection day 1 , day 15 day 29 every 28 day thereafter . - Participants physical examination blood work perform treatment date . After teh study treatment complete , physical examination do every three month first 2 year , every 6 month year 2-5 , annually 5 year . - Participants may remain study treatment disease progression experience serious side effect .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Female 18 year age old Histologically confirm adenocarcinoma breast progress localregional metastatic disease consider amenable curative treatment Evidence hormone sensitivity primary secondary tumor tissue Postmenopausal define criterion list protocol May adjuvant endocrine therapy discontinue least 12 month prior inclusion . Subjects minimal exposure adjuvant first line metastatic endocrine treatment 12 month prior study enrollment eligible overall PI sponsor permission Prior trastuzumab biologic therapy allow , must discontinue 2 week prior inclusion Presence measurable evaluable , nonmeasurable , disease . Any xrays scan assessment measurable disease must perform 28 day prior registration Eastern Cooperative Oncology Group ( ECOG ) performance status 0,1 2 Presence lifethreatening metastatic disease Endocrine therapy advance disease set Systemic chemotherapy , whether adjuvant therapy advance disease , within previous 4 week Trastuzumab biologic therapy within previous 2 week Extensive radiation therapy within last 2 week Prior adjuvant neoadjuvant treatment fulvestrant allow Concomitant anticancer treatment Chronic bisphosphonates hypercalcemia prevention bone metastases Subjects receive longterm anticoagulant therapy warfarin Estrogen replacement therapy within 6 month trial entry Previous current system malignancy within past 3 year Treatment non approve investigational drug within 2 week study entry Any evidence severe uncontrolled systemic disease History bleed diathesis Any severe concomitant condition make undesirable subject participate study would jeopardize compliance study protocol</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>hormone receptor positive breast cancer</keyword>
	<keyword>Fulvestrant</keyword>
</DOC>